About Panavance Therapeutics

We are focused on giving every patient the best possible chance to live a healthy and cancer-free life. Our clinical-stage drug GP-2250 is bringing new hope to the fight against cancer through truly novel science.

About Panavance Mother Daughter

Who We Are

Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the outcomes and quality of life for cancer patients. Panavance, a US Delaware company, is located in Berwyn, PA. The company was founded in 2021 and is a subsidiary of Swiss privately held Ed. Geistlich Söhne AG für Chemische Industrie.

Panavance’s lead program, misetionamide (also known as GP-2250), is a tumor cell selective and broadly active small molecule with a unique dual mechanism of action of selectively disrupting the energy metabolism of cancer cells leading to cancer cell death as well as impacting nuclear factor-κB (“NFκB”) which effects cancer cells’ ability for protein synthesis and DNA transcription thereby restricting cancer cell growth and proliferation.

The Company is progressing towards the initiation of registration directed clinical studies in two tumor types: a Phase 2/3 trial of misetionamide for the treatment of platinum-resistant ovarian cancer is anticipated to start late 2024 to early 2025, and a Phase 2/3 trial as a first-line maintenance therapy for non-BRCA mutated pancreatic cancer patients, a population for which there are no FDA approved drugs, expected to start 2025. Misetionamide’s unique mechanism of action and extensive preclinical data supports broad oncology utility with the potential to be effective in additional indications, including melanoma, squamous cell, breast and colorectal cancers.

Why We Exist

We get up every morning with a clear focus on making a significant improvement in clinical outcomes and the lives of cancer patients everywhere. Like the mechanism of GP-2250, our mission is to disrupt cancer’s energy.

What We Deliver

Our clinical stage asset, GP-2250, has the potential to make a meaningful impact across diverse oncological disease states and therapeutic applications by targeting the primary source of cancer cell energy production with its unique and patent-pending mechanism of action.

Request More Information

Father Son Cancer Survivor

What’s In A Name?
Why We’re Panavance.

Pan Disease Icon


We believe that our highly tumor cell selective asset may offer a broad benefit across and beyond cancers and in combination with existing treatments.

Pan Therapeutic Icon


GP-2250 has broad therapeutic potential across stages of disease including neoadjuvant, adjuvant and advanced/metastatic disease.

Pan Avance


We are focused on advancing the effectiveness of cancer treatments and quality of life for patients everywhere.

Meet Leadership Team


Meet the Panavance leadership team.

We are led by a highly capable and passionate team that wholeheartedly shares our mission.

Read More

Our Science Image


Discover our novel mechanism of action.

Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.

Read More